FY2017 EPS Estimates for Flexion Therapeutics Inc (FLXN) Cut by Analyst

Flexion Therapeutics Inc (NASDAQ:FLXN) – Analysts at Cantor Fitzgerald decreased their FY2017 EPS estimates for Flexion Therapeutics in a research note issued on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Russo now anticipates that the specialty pharmaceutical company will post earnings per share of ($4.69) for the year, down from their prior forecast of ($3.99). Cantor Fitzgerald has a “Overweight” rating and a $34.00 price objective on the stock.

A number of other analysts also recently issued reports on the company. Royal Bank of Canada set a $44.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Sunday, March 26th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a research note on Saturday, March 25th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 14th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Flexion Therapeutics in a research note on Saturday, March 11th. Finally, BMO Capital Markets reaffirmed a “positive” rating and issued a $33.00 price objective on shares of Flexion Therapeutics in a research note on Tuesday, February 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.68.

TRADEMARK VIOLATION NOTICE: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2017/04/21/fy2017-earnings-estimate-for-flexion-therapeutics-inc-issued-by-cantor-fitzgerald-flxn-updated-updated.html.

Flexion Therapeutics (NASDAQ:FLXN) traded down 2.19% during midday trading on Thursday, reaching $26.37. 320,694 shares of the company’s stock traded hands. Flexion Therapeutics has a one year low of $8.16 and a one year high of $29.41. The stock’s 50 day moving average price is $24.28 and its 200-day moving average price is $20.44. The stock’s market cap is $836.75 million.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Thursday, March 9th. The specialty pharmaceutical company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by $0.07.

A number of institutional investors have recently made changes to their positions in FLXN. Keybank National Association OH increased its position in shares of Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 67 shares during the period. SECOR Capital Advisors LP acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $214,000. Stoneridge Investment Partners LLC acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $271,000. Jennison Associates LLC acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $402,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $620,000. 62.25% of the stock is currently owned by institutional investors.

In other Flexion Therapeutics news, CFO Frederick W. Driscoll sold 3,000 shares of the company’s stock in a transaction on Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the transaction, the chief financial officer now owns 10,777 shares of the company’s stock, valued at approximately $247,871. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Neil Bodick sold 5,000 shares of the company’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $28.23, for a total value of $141,150.00. Following the completion of the transaction, the insider now directly owns 46,137 shares in the company, valued at approximately $1,302,447.51. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,000 shares of company stock worth $407,950. Corporate insiders own 18.00% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

5 Day Chart for NASDAQ:FLXN

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply